πŸ‡ΊπŸ‡Έ FDA
Patent

US 10160753

Indazole compounds as IRAK4 inhibitors

granted A61PA61P1/02A61P1/16

Quick answer

US patent 10160753 (Indazole compounds as IRAK4 inhibitors) held by Aurigene Discovery Technologies Limited expires Mon Dec 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Aurigene Discovery Technologies Limited
Grant date
Tue Dec 25 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
42
CPC classes
A61P, A61P1/02, A61P1/16, A61P1/18, A61P11/06